Lytix Biopharma AS (LYTIX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.969x

Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has a cash flow conversion efficiency ratio of -0.969x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.85 Million ≈ $-6.30 Million USD) by net assets (Nkr61.75 Million ≈ $6.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lytix Biopharma AS market capitalisation for the company's overall valuation and market capitalisation.

Lytix Biopharma AS - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Lytix Biopharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lytix Biopharma AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lytix Biopharma AS ranked by their cash flow conversion efficiency. See LYTIX cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Seco/Warwick SA WAR:SWG	-0.098x
SLP Resources Bhd KLSE:7248	0.017x
Maan Aluminium Limited NSE:MAANALU	0.076x
SUI Group Holdings Limited NASDAQ:SUIG	-0.023x
Emkay Global Financial Services Limited NSE:EMKAY	-0.048x
Case Group AB ST:CASE	-0.001x
SM Culture & Contents Co. Ltd KQ:048550	0.055x
Groupe LDLC SA PA:ALLDL	-0.164x

Annual Cash Flow Conversion Efficiency for Lytix Biopharma AS (2017–2025)

The table below shows the annual cash flow conversion efficiency of Lytix Biopharma AS from 2017 to 2025. View latest Lytix Biopharma AS stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Nkr61.75 Million ≈ $6.50 Million	Nkr-59.85 Million ≈ $-6.30 Million	-0.969x	-48.60%
2024-12-31	Nkr107.89 Million ≈ $11.35 Million	Nkr-70.37 Million ≈ $-7.41 Million	-0.652x	+65.12%
2023-12-31	Nkr51.32 Million ≈ $5.40 Million	Nkr-95.97 Million ≈ $-10.10 Million	-1.870x	-385.00%
2022-12-31	Nkr135.13 Million ≈ $14.22 Million	Nkr-52.10 Million ≈ $-5.48 Million	-0.386x	-62.86%
2021-12-31	Nkr189.62 Million ≈ $19.95 Million	Nkr-44.90 Million ≈ $-4.72 Million	-0.237x	+80.66%
2020-12-31	Nkr19.89 Million ≈ $2.09 Million	Nkr-24.35 Million ≈ $-2.56 Million	-1.224x	+54.85%
2019-12-31	Nkr13.58 Million ≈ $1.43 Million	Nkr-36.82 Million ≈ $-3.87 Million	-2.711x	-53.27%
2018-12-31	Nkr41.05 Million ≈ $4.32 Million	Nkr-72.62 Million ≈ $-7.64 Million	-1.769x	+70.06%
2017-12-31	Nkr11.79 Million ≈ $1.24 Million	Nkr-69.67 Million ≈ $-7.33 Million	-5.909x	--

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$68.78 Million

Nkr653.65 Million NOK

Market Cap Rank

#20759 Global

#186 in Norway

Share Price

Nkr8.50

Change (1 day)

+1.43%

52-Week Range

Nkr6.90 - Nkr11.50

All Time High

Nkr18.60